Formation Bio snaps up global rights to next-gen CNS TYK2 inhibitor from Lynk Pharma
LNK01006 is designed to deliver potent, selective inhibition of TYK2-mediated cytokine signaling with central nervous system exposure
LNK01006 is designed to deliver potent, selective inhibition of TYK2-mediated cytokine signaling with central nervous system exposure
Subscribe To Our Newsletter & Stay Updated